MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Last update at 2024-01-23T20:01:58.471697Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 34.77M | -9.72100M | -68.87600M | -55.35000M | -65.33600M |
| Minority interest | - | - | - | - | - |
| Net income | 35.38M | -25.68700M | -69.78700M | -53.53600M | -65.33600M |
| Selling general administrative | 23.86M | 20.94M | 18.91M | 16.39M | 18.24M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 110.78M | 85.08M | 16.60M | 6.68M | 0.90M |
| Reconciled depreciation | 1.29M | 1.25M | 0.73M | 2.03M | 0.97M |
| Ebit | 14.54M | -4.59700M | -56.82100M | -52.45500M | -65.98700M |
| Ebitda | 16.16M | -4.58200M | -56.73200M | -53.76100M | -65.01200M |
| Depreciation and amortization | 1.62M | 0.01M | 0.09M | -1.30600M | 0.97M |
| Non operating income net other | 23.26M | -2.28000M | -10.49900M | - | - |
| Operating income | 14.54M | -4.59700M | -56.82100M | -52.45500M | -65.02200M |
| Other operating expenses | 96.24M | 89.67M | 73.42M | 59.13M | 65.92M |
| Interest expense | 3.03M | 2.84M | 1.56M | 1.52M | 1.49M |
| Tax provision | -0.60900M | 15.97M | - | - | - |
| Interest income | 0.98M | 2.80M | 1.24M | 0.83M | 1.05M |
| Net interest income | -3.03100M | -2.84400M | -1.55600M | -1.51900M | -1.49400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.60900M | 15.97M | 0.91M | -1.81400M | 1.18M |
| Total revenue | 110.78M | 85.08M | 16.60M | 6.68M | 0.90M |
| Total operating expenses | 96.24M | 89.67M | 73.42M | 59.13M | 65.92M |
| Cost of revenue | - | - | - | 42.74M | 47.69M |
| Total other income expense net | 20.23M | -5.12400M | -12.05500M | -2.89500M | 1.18M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
| Net income applicable to common shares | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 165.89M | 159.88M | 165.44M | 99.57M | 44.48M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.78M | 6.47M | 5.43M | 1.77M | 4.67M |
| Total liab | 72.06M | 137.36M | 183.44M | 91.17M | 49.90M |
| Total stockholder equity | 93.83M | 22.52M | -18.00600M | 8.40M | -5.41800M |
| Deferred long term liab | - | - | 0.37M | - | - |
| Other current liab | 14.08M | 11.13M | 8.15M | 13.49M | 11.70M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
| Retained earnings | -394.93700M | -430.31600M | -404.62900M | -335.75300M | -280.40300M |
| Other liab | - | 36.84M | 67.45M | 56.23M | 14.76M |
| Good will | - | - | - | - | - |
| Other assets | 1.34M | 0.16M | 12.70M | 1.38M | 0.28M |
| Cash | 106.44M | 114.06M | 138.69M | 89.89M | 37.40M |
| Cash and equivalents | 106.44M | 114.06M | 138.69M | 89.89M | 37.40M |
| Total current liabilities | 25.08M | 72.25M | 81.55M | 34.94M | 35.14M |
| Current deferred revenue | 0.59M | 53.88M | 72.05M | 1.67M | 0.96M |
| Net debt | -68.51300M | -78.77600M | -103.33700M | -70.61600M | -16.01800M |
| Short term debt | 10.08M | 7.01M | 0.91M | 19.28M | 21.39M |
| Short long term debt | 8.48M | 5.96M | - | 18.91M | 21.39M |
| Short long term debt total | 37.92M | 35.28M | 35.35M | 19.28M | 21.39M |
| Other stockholder equity | 493.31M | 457.39M | 391.18M | 348.66M | 279.54M |
| Property plant equipment | 2.79M | 2.14M | 1.40M | 1.52M | 2.13M |
| Total current assets | 148.14M | 144.44M | 151.34M | 96.67M | 42.08M |
| Long term investments | 2.00M | 2.00M | - | - | - |
| Net tangible assets | 93.83M | 22.52M | -18.00600M | 8.40M | -5.41800M |
| Short term investments | 28.16M | 14.00M | - | - | 0.00000M |
| Net receivables | 9.76M | 9.91M | 7.22M | 5.00M | - |
| Long term debt | 17.79M | 19.67M | 24.79M | - | 0.00000M |
| Inventory | - | - | - | - | - |
| Accounts payable | 0.32M | 0.22M | 0.44M | 0.50M | 1.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.55800M | -4.56600M | -4.56300M | -4.52300M | -4.55700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.01M | 0.01M | 0.01M | 0.00900M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -394.93700M | -430.31600M | -404.62900M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.34M | 1.47M | 1.75M | 1.38M | 0.28M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 17.75M | 15.44M | 14.09M | 2.90M | 2.41M |
| Capital lease obligations | 11.66M | 9.65M | 10.55M | 0.37M | - |
| Long term debt total | 17.79M | 19.67M | 24.79M | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -13.80100M | -16.05500M | -0.74100M | 0.23M | 25.27M |
| Change to liabilities | 1.70M | 1.44M | -2.81800M | -0.26300M | -0.61700M |
| Total cashflows from investing activities | -15.00200M | -17.14000M | -0.74100M | 0.23M | 25.27M |
| Net borrowings | - | - | 1.04M | -2.80000M | -2.80000M |
| Total cash from financing activities | 39.22M | 52.90M | 14.43M | 105.04M | 0.70M |
| Change to operating activities | - | -0.39000M | -7.17900M | 0.78M | -0.16400M |
| Net income | 35.38M | -25.68700M | -68.87600M | -55.35000M | -65.33600M |
| Change in cash | -7.39800M | -24.62800M | 48.51M | 53.87M | -33.34500M |
| Begin period cash flow | 115.44M | 140.06M | 91.55M | 37.68M | 71.03M |
| End period cash flow | 108.04M | 115.44M | 140.06M | 91.55M | 37.68M |
| Total cash from operating activities | -31.63100M | -60.38200M | 34.88M | -51.43500M | -59.16100M |
| Issuance of capital stock | 38.98M | 51.96M | 12.38M | 107.66M | 0.00000M |
| Depreciation | 1.29M | 1.25M | 0.73M | 2.03M | 0.97M |
| Other cashflows from investing activities | -13.80100M | -16.05500M | 0.07M | 0.28M | 26.16M |
| Dividends paid | - | - | -0.18400M | -0.02800M | - |
| Change to inventory | - | 0.21M | -7.17900M | 0.78M | - |
| Change to account receivables | 3.32M | -2.69000M | -2.22400M | -5.00000M | -5.00000M |
| Sale purchase of stock | 0.19M | 0.16M | 0.18M | 0.03M | 0.20M |
| Other cashflows from financing activities | 0.05M | 0.78M | 21.37M | 0.18M | 0.50M |
| Change to netincome | -8.88200M | 11.07M | 16.89M | 6.37M | 5.98M |
| Capital expenditures | 1.20M | 1.08M | 0.81M | 0.05M | 0.88M |
| Change receivables | 3.32M | -2.69000M | -2.22400M | - | - |
| Cash flows other operating | -64.06100M | -45.82800M | 91.17M | - | - |
| Exchange rate changes | - | -0.00300M | -0.05800M | - | - |
| Cash and cash equivalents changes | -7.41800M | -24.62800M | 48.51M | - | - |
| Change in working capital | -60.37700M | -48.19400M | 85.00M | -4.48100M | -0.78100M |
| Stock based compensation | 11.19M | 7.72M | 5.42M | 5.16M | 5.71M |
| Other non cash items | -19.11400M | 2.13M | 1.75M | 0.40M | 0.45M |
| Free cash flow | -32.83200M | -61.46700M | 34.07M | -51.48200M | -60.04500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SELB Selecta Biosciences Inc |
- -% | - | - | 25.45 | 1.54 | 2.36 | 0.74 | 2.01 |
| NVO Novo Nordisk A/S |
-2.29 1.74% | 129.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
3.80 2.90% | 135.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.67 0.75% | 494.48 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
22.92 2.16% | 1083.78 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street, Watertown, MA, United States, 02472
| Name | Title | Year Born |
|---|---|---|
| Dr. Carsten Brunn Ph.D. | CEO, Pres & Director | 1971 |
| Ms. Ann K. Donohue CPA | VP of Fin. & Controller | 1982 |
| Dr. Lloyd Johnston Ph.D. | Chief Operating Officer | 1968 |
| Dr. Takashi Kei Kishimoto Ph.D. | Chief Scientific Officer | 1960 |
| Dr. Peter G. Traber M.D. | Chief Medical Officer | 1955 |
| Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D. | Co-Founder and Co-Chair of the Scientific Advisory Board | NA |
| Mr. Blaine T. Davis | Chief Financial Officer | 1974 |
| Mr. Matthew Bartholomae J.D. | Gen. Counsel & Sec. | NA |
| Ms. Kristen Baldwin | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...